| College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer AC Wolff, ME Hammond, JN Schwartz, KL Hagerty, DC Allred, RJ Cote, ... J clin oncol 25 (1), 118-145, 2007 | 5985 | 2007 |
| Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice … AC Wolff, MEH Hammond, DG Hicks, M Dowsett, LM McShane, ... Journal of clinical oncology 31 (31), 3997-4013, 2013 | 5423 | 2013 |
| College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer ME Hammond, DF Hayes, M Dowsett, DC Allred, KL Hagerty, S Badve, ... J Clin Oncol 28 (16), 2784-2795, 2010 | 5394 | 2010 |
| Circulating tumor cells, disease progression, and survival in metastatic breast cancer M Cristofanilli, GT Budd, MJ Ellis, A Stopeck, J Matera, MC Miller, ... New England Journal of Medicine 351 (8), 781-791, 2004 | 5325 | 2004 |
| ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome C Ginestier, MH Hur, E Charafe-Jauffret, F Monville, J Dutcher, M Brown, ... Cell stem cell 1 (5), 555-567, 2007 | 4882 | 2007 |
| Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 A Goldhirsch, EP Winer, AS Coates, RD Gelber, M Piccart-Gebhart, ... Annals of oncology 24 (9), 2206-2223, 2013 | 4375 | 2013 |
| American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in … MEH Hammond, DF Hayes, M Dowsett, DC Allred, KL Hagerty, S Badve, ... Archives of pathology & laboratory medicine 134 (7), e48-e72, 2010 | 3951 | 2010 |
| American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer AC Wolff, MEH Hammond, JN Schwartz, KL Hagerty, DC Allred, RJ Cote, ... Journal of clinical oncology 25 (1), 118-145, 2006 | 3840 | 2006 |
| American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer L Harris, H Fritsche, R Mennel, L Norton, P Ravdin, S Taube, ... Journal of clinical oncology 25 (33), 5287-5312, 2007 | 3322 | 2007 |
| Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 AS Coates, EP Winer, A Goldhirsch, RD Gelber, M Gnant, ... Annals of oncology 26 (8), 1533-1546, 2015 | 2260 | 2015 |
| Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials Early Breast Cancer Trialists' Collaborative Group The Lancet 379 (9814), 432-444, 2012 | 2217 | 2012 |
| Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer JA Sparano, RJ Gray, DF Makower, KI Pritchard, KS Albain, DF Hayes, ... New England Journal of Medicine 379 (2), 111-121, 2018 | 2073 | 2018 |
| Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group M Dowsett, TO Nielsen, R A’Hern, J Bartlett, RC Coombes, J Cuzick, ... Journal of the National cancer Institute 103 (22), 1656-1664, 2011 | 2054 | 2011 |
| EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells CG Kleer, Q Cao, S Varambally, R Shen, I Ota, SA Tomlins, D Ghosh, ... Proceedings of the national academy of sciences 100 (20), 11606-11611, 2003 | 1995 | 2003 |
| ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer GY Locker, S Hamilton, J Harris, JM Jessup, N Kemeny, JS Macdonald, ... Journal of clinical oncology 24 (33), 5313-5327, 2006 | 1986 | 2006 |
| Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women … P McGale, C Taylor, C Correa, D Cutter, F Duane, M Ewertz, R Gray, ... Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews …, 2014 | 1883* | 2014 |
| Revision of the American Joint Committee on Cancer staging system for breast cancer SE Singletary, C Allred, P Ashley, LW Bassett, D Berry, KI Bland, ... Journal of clinical oncology 20 (17), 3628-3636, 2002 | 1804 | 2002 |
| Prognostic factors in breast cancer: College of American Pathologists consensus statement 1999 PL Fitzgibbons, DL Page, D Weaver, AD Thor, DC Allred, GM Clark, ... Archives of pathology & laboratory medicine 124 (7), 966-978, 2000 | 1794 | 2000 |
| Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast … IC Henderson, DA Berry, GD Demetri, CT Cirrincione, LJ Goldstein, ... Journal of clinical oncology 21 (6), 976-983, 2003 | 1732 | 2003 |
| Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a … KS Albain, WE Barlow, S Shak, GN Hortobagyi, RB Livingston, IT Yeh, ... The lancet oncology 11 (1), 55-65, 2010 | 1607 | 2010 |
